Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Bausch Health Companies Inc. (“Bausch” or the “Company”) (NYSE: BHC) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 4, 2023, Bausch released its first quarter 2023 financial results, revealing negative earnings, indicating further delay of its B+L spinoff share distribution, w.

The Law Offices of Frank R. Cruz Announces Investigation of Bausch Health Companies Inc. (BHC) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $BHC #BauschHealthCompaniesInc--Bausch Health Companies Inc. (BHC) Misled Investors Regarding the Benefits of its Spin Off of B+L.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Bausch Health Companies Inc. (BHC)

NEW YORK , July 27, 2023 /PRNewswire/ -- Bernstein Liebhard LLP: Do you, or did you, own securities of Bausch Health Companies Inc. (NYSE: BHC)? Did you purchase your securities between August 6, 2020 and May 3, 2023, inclusive?

BAUSCH HEALTH COMPANIES INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bausch Health Companies Inc. (NYSE: BHC)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between August 6, 2020 and May 3, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 25, 2023. SO WHAT: If you purchased Bausch securities during the Clas.

BHC EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHC

Scholarships Awarded to Six Students Affected by Dermatologic Conditions LAVAL, QC / ACCESSWIRE / July 27, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the recipients of their 2023 Aspire Higher Scholarship program. The program, which has provided a total of $978,000 in scholarships since launching in 2013, will award six students who have been treated for a dermatologic condition with a scholarship of up to $10,000 to pursue their undergraduate or graduate degrees.

Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients

NEW YORK , July 27, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Bausch Health Companies Inc. ("Bausch Health") (NYSE: BHC) concerning possible violations of federal securities laws. The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan.

BHC INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Bausch Health Companies Inc.

NEW YORK , July 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Bausch Health Companies Inc.: The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan. On May 10, 2022, Bausch Health announced its first-quarter 2022 results, prompting the stock price to fall $3.50 per share.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Bausch Health Companies Inc. of an Investigation and Potential Class Action Lawsuit - (NYSE: BHC)

NEW YORK , July 25, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Bausch Health Companies Inc. ("Bausch Health") (NYSE: BHC) violated federal securities laws. CURRENT INVESTIGATION DETAILS:The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan.

BHC NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Bausch Health Companies Inc.

NEW YORK , July 24, 2023 /PRNewswire/ -- Attention Bausch Health Companies Inc. ("Bausch Health") (NYSE: BHC) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Bausch Health and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan.

BHC ALERT: The Law Offices of Vincent Wong Investigate Bausch Health Companies Inc. for Potential Violations of Securities Laws

NEW YORK , July 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Bausch Health Companies Inc. (NYSE: BHC) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/bausch-health-class-action-loss-submission-form/?id=42395&from=4 Further details on the investigation: The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan.   On May 10, 2022, Bausch Health announced its first-quarter 2022 results, prompting the stock price to fall $3.50 per share.

BHC FRAUD ALERT: Jakubowitz Law is Investigating Bausch Health Companies Inc. in Connection with Potential Violations of Federal Securities Laws

LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3

For Fourth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / July 11, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program. For the fourth consecutive year, Salix will be awarding $10,000 each to 10 students living with a GI disease.

Salix Announces 2023 Gastrointestinal Health Scholars Program Winners

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2023 financial results on Wednesday, Aug. 2, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start o.

Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2

Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.

Bausch Health (BHC) Secures $600M Financing Facility, Stock Up

The pharmaceutical company has entered into a $600 million financing facility with investment management giant KKR. Bausch said it plans to use the extra funds for general corporate purposes.

Why Shares of Bausch Health Jumped on Friday

Shares of Bausch Health Companies Inc. BHC, -1.03% rallied 2.1% in premarket trading Friday, after the pharmaceutical company announced a $600 million financing facility with KKR & Co. Inc. KKR, -2.46%, an alternative asset management firm. Bausch Health said it plans to use the proceeds from the facility, which provides access to additional liquidity for five years, for general corporate purposes.

Bausch Health's stock rallies after $600 million financing agreement with KKR

Oral Health Care Companies Celebrate the 100th ADHA Conference by Highlighting New Data for the Treatment of Periodontal Disease LAVAL, QC / ACCESSWIRE / July 7, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) and its oral health care business, OraPharma, today announced its presence at the American Dental Hygienists' Association (ADHA®) Annual Conference held in Chicago, IL from July 7-9, 2023. ADHA is the largest and oldest organization representing the professional interests of more than 226,000 dental hygienists in the United States.

OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference

Bausch + Lomb purchased Blink brands from a J&J subsidiary for $106.5 million to expand its over-the-counter offerings.

Bausch + Lomb Buys Blink Brands to Expand Eye Drop Portfolio

Bausch + Lomb Corporation was spun out of Bausch Health Companies Inc. this year - after years of speculation - and the new entity is an eye disease specialist. The parent company owns nearly 90% of the spun-out company's stock. Bausch + Lomb announced at the end of last month it would acquire Novartis dry eye disease asset XIIDRA and other assets in a deal worth up to $2.5bn.

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Johnson & Johnson

Bausch + Lomb said on Thursday it has acquired Johnson & Johnson's eye and contact lens drops for $106.5 million in an all-cash deal to expand its portfolio of over-the-counter eye care products.

Bausch + Lomb buys J&J's dry eye relief drops for $107 mln

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb today announced the purchase of the Blink® product line of OTC eye and contact lens drops from Johnson & Johnson Vision.

Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

Novartis

Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.

Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care Portfolio

Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two companies reached an agreement Friday for a portion of Novartis' eye medicine portfolio, as Novartis shifts its focus towards the development of new and more profitable drugs.

Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B deal

Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Bausch + Lomb will make an upfront payment of $1.75 billion in cash, and could make milestone payments of up to $750 million based based on sales and commercialization thresholds.

Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal

Bausch + Lomb Corp

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.

News for Bausch Health Companies Inc Stock (BHC)